EPS for ADMA Biologics, Inc. (ADMA) Expected At $-0.51; Cyberoptics (CYBE) Sentiment Is 1.36

February 18, 2018 - By Ellis Scott

Analysts expect ADMA Biologics, Inc. (NASDAQ:ADMA) to report $-0.51 EPS on February, 23.They anticipate $0.16 EPS change or 45.71% from last quarter’s $-0.35 EPS. After having $0.59 EPS previously, ADMA Biologics, Inc.’s analysts see -186.44% EPS growth. The stock decreased 1.27% or $0.05 during the last trading session, reaching $3.89. About 69,501 shares traded. ADMA Biologics, Inc. (NASDAQ:ADMA) has declined 37.56% since February 18, 2017 and is downtrending. It has underperformed by 54.26% the S&P500.

CyberOptics Corporation is a developer and maker of high precision sensing technology solutions worldwide. The company has market cap of $99.43 million. The companyÂ’s sensors are being used in general purpose metrology and 3D scanning, surface mount technology , and semiconductor markets to improve yields and productivity. It has a 14.68 P/E ratio. It offers SMT electronic assembly alignment sensor products, including LaserAlign sensors for incorporation into pick-and-place machines; BoardAlign Camera that identifies fiducial markings on a circuit board and aligns the board in the pick-and-place machine prior to component placement; and InPrinter Inspection Camera, which identifies fiducial markings on a circuit board to ensure accurate board registration prior to placement of solder paste.

Investors sentiment increased to 1.14 in 2017 Q3. Its up 0.58, from 0.56 in 2017Q2. It increased, as 4 investors sold ADMA Biologics, Inc. shares while 3 reduced holdings. 3 funds opened positions while 5 raised stakes. 7.02 million shares or 6.17% less from 7.48 million shares in 2017Q2 were reported. Prelude Capital Mgmt holds 0.01% or 39,000 shares in its portfolio. Tower Rech Capital (Trc) invested in 11,673 shares. Bank & Trust Of America Corp De stated it has 4 shares. Renaissance Limited Liability Company stated it has 20,300 shares. Bancorp Of New York Mellon has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Morgan Stanley holds 0% in ADMA Biologics, Inc. (NASDAQ:ADMA) or 4,863 shares. Aisling Ltd Liability Corp invested in 1.83% or 3.61 million shares. Royal Retail Bank Of Canada reported 2 shares. Iguana Mngmt Limited Com holds 565,000 shares. Northern Tru Corporation has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Geode Cap Lc reported 21,526 shares stake. Vanguard Group Incorporated Inc invested 0% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA). 19,078 are owned by Millennium Ltd Liability. 372,700 are owned by Fmr Limited Liability Corporation. Consonance Capital Mngmt Lp accumulated 0.43% or 1.27 million shares.

ADMA Biologics, Inc., a biopharmaceutical company, develops, makes, and markets specialty plasma biologics for the treatment of immune deficiencies and infectious diseases. The company has market cap of $176.28 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

Among 2 analysts covering ADMA Biologics (NASDAQ:ADMA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ADMA Biologics has $15 highest and $1300 lowest target. $14’s average target is 259.90% above currents $3.89 stock price. ADMA Biologics had 8 analyst reports since September 9, 2015 according to SRatingsIntel. Maxim Group maintained the shares of ADMA in report on Wednesday, June 7 with “Buy” rating. The rating was upgraded by Raymond James on Tuesday, November 14 to “Outperform”. Raymond James downgraded the shares of ADMA in report on Monday, August 1 to “Market Perform” rating. The rating was maintained by Maxim Group with “Buy” on Thursday, September 17. Maxim Group upgraded ADMA Biologics, Inc. (NASDAQ:ADMA) rating on Monday, January 23. Maxim Group has “Buy” rating and $13 target. On Monday, August 1 the stock rating was downgraded by Maxim Group to “Hold”. The stock of ADMA Biologics, Inc. (NASDAQ:ADMA) earned “Strong Buy” rating by Raymond James on Wednesday, September 9. Maxim Group maintained the shares of ADMA in report on Wednesday, June 28 with “Buy” rating.

Ratings analysis reveals 100% of CyberOptics’s analysts are positive. Out of 2 Wall Street analysts rating CyberOptics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $20.0 while the high is $27.0. The stock’s average target of $23.50 is 64.91% above today’s ($14.25) share price. CYBE was included in 2 notes of analysts from August 26, 2016. Dougherty & Company initiated it with “Buy” rating and $27.0 target in Wednesday, September 7 report. Lake Street initiated CyberOptics Corporation (NASDAQ:CYBE) rating on Friday, August 26. Lake Street has “Buy” rating and $20.0 target.

Analysts await CyberOptics Corporation (NASDAQ:CYBE) to report earnings on February, 27. They expect $-0.07 EPS, down 163.64% or $0.18 from last year’s $0.11 per share. After $-0.01 actual EPS reported by CyberOptics Corporation for the previous quarter, Wall Street now forecasts 600.00% negative EPS growth.

The stock decreased 6.25% or $0.95 during the last trading session, reaching $14.25. About 59,798 shares traded. CyberOptics Corporation (CYBE) has risen 33.75% since February 18, 2017 and is uptrending. It has outperformed by 17.05% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>